Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to developing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases influenced by protein growth factors, today announced…
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been conditionally approved in China for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have…
Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases, has announced its financial results for the second quarter of 2024. “This quarter marks a groundbreaking milestone in Duchenne…
Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, has announced its unaudited financial results and notable corporate developments for the second quarter of 2024. CEO Statement Ying…
Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK), a leading innovation-driven pharmaceutical company in China, and Guangzhou Lupeng Pharmaceutical Co., Ltd. (Lupeng Pharma), which specializes in treatments for malignant tumors…
Bio-Techne’s fourth quarter organic revenue increased by 1% (2% reported) to $306.1 million. For the full year, organic revenue rose by 1% (2% reported) to $1.2 billion. GAAP earnings per…
WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Medigene AG (FSE: MDG1, Prime Standard) have announced a three-year strategic partnership. The collaboration aims to design…
Royalty Pharma today released its financial results for the second quarter of 2024 and announced an increase in its full-year guidance for Portfolio Receipts. We achieved double-digit growth in Portfolio…
Today, the European Commission (EC) approved ADZYNMA®▼ (recombinant ADAMTS13) for treating ADAMTS13 deficiency in both children and adults with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA is now the first and…
Vertex Announces Reimbursement Agreement with NHS England for CASGEVY™ Vertex has announced a new reimbursement agreement with NHS England, effective immediately, allowing eligible patients with transfusion-dependent beta thalassemia (TDT) to…
Recent findings from the two-part, double-randomized GMMG-HD7 phase 3 study reveal that Sarclisa (isatuximab), combined with lenalidomide, bortezomib, and dexamethasone (RVd), significantly enhances progression-free survival (PFS) in newly diagnosed, transplant-eligible…
Novartis announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta® (iptacopan), a first-in-class complement inhibitor designed to reduce proteinuria in adults with primary immunoglobulin…